Key Points Bristol Myers Squibb maintains strong positions in oncology and neuroscience with high free cash flow generation. Pfizer is undergoing a major transformation by acquiring high-growth businesses in oncology and obesity care. Which of these pharmaceutical giants is the better buy for your portfolio heading into 2026? 10 stocks we like better than Bristol Myers Squibb › Healthcare investors often weigh the dividends and pipelines of industry titans. Are you looking for the steady cash flows of Bristol Myers Squibb (NYSE:BMY) or the ambitious transformation currently underway at Pfizer (NYSE:PFE) ? These two drugmakers are often compared because they both face upcoming patent expirations on blockbuster medications.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.